



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: KUZ0035US.NP

Inventors: Fijinaga et al.

Serial No.: 10/594,887

Filing Date: Not Assigned

Examiner: Not Assigned

Customer No.: 26259


Group Art Unit: Not Assigned

Confirmation No.: Not Assigned

Title: Remedy for Prion Disease and Method of  
Producing the Same

I, Kathleen A. Tyrrell, Registration No. 38,350,  
certify that this correspondence is being deposited  
with the U.S. Postal Service as First Class mail in  
an envelope addressed to the Commissioner for Patents  
P.O. Box 1450, Alexandria, VA 22313-1450

On this date: November 28, 2006


 Kathleen A. Tyrrell, Registration No. 38,350

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

## INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56 (b).

(xx) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

( ) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

( ) Certification in Accordance with §1.97(e) is attached hereto; or

( ) Authorization to charge Deposit Account No. 50-1619 the fee of \$180.00 as set forth in §1.17(p) is provided.

( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).

(xx) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith with the exception of U.S. Patents and U.S. Published Applications.


( ) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. \_\_\_\_\_, filed \_\_\_\_\_, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

( ) The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) References AD, AE, AF, AG and BA through BY are in the English language. References AA, AB, AC, AH, AI, AJ, AK and AL are in a Foreign language and English abstracts or abridged English translations are provided. Reference AD relates to Reference AE and Reference AF relates to Reference AG.


Respectfully submitted,

  
Kathleen A. Tyrrell  
Registration No. 38,350

Date: November 28, 2006

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515



Form 1449 Modified  
List of Patents and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce

Docket No.  
**KUZ0035US.NP**

Sheet 01 of 06

Applicant  
Fujinaga et al.

Filing Date  
**Not Assigned**


U. S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Country	Translation YES	NO
AA	2003-040778	2-13-03	Japan	Abridged English Translation	
AB	2004-081034	3-18-04	Japan	Abridged English Translation	
AC	WO 03/038074	5-8-03	Japan	English Abstract	
AD	2000-512131	9-19-00	Japan	Relates to AE	
AE	WO 97/45746	12-4-97	PCT	X	

## EXAMINER

**DATE CONSIDERED**



Form PTO-144 ~~GRANTED~~ **Cited**  
List of Patents and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce

Docket No.  
**KUZ0035US.NP**

Sheet 02 of 06

Applicant  
Fujinaga et al.

Filing Date  
**Not Assigned**


U. S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Country	Translation YES	NO
AF	2004-501626	1-22-04	Japan	Relates to AG	
AG	WO 2002/00713	1-3-02	PCT	X	
AH	2002-330789	11-19-02	Japan	Abridged English Translation	
AI	WO 03/038075	5-8-03	Japan	English Abstract	
AJ	2003-144148	5-20-03	Japan	Abridged English Translation	

**EXAMINER**

**DATE CONSIDERED**



~~SEARCHED~~ ~~INDEXED~~ ~~MAILED~~  
**Form PTO-1449 Modified**  
List of Patents and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce

Docket No.  
**KUZ0035US.NP**

Sheet 03 of 06

Applicant  
Fujinaga et al.

Filing Date  
**Not Assigned**

Group  
**Not Assigned**


U. S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES	NO
	AK	2003-321498	11-11-03	Japan	Abridged English Translation	
	AL	2003-149237	5-21-03	Japan	Abridged English Translation	

**EXAMINER**

**DATE CONSIDERED**




Form PTO-1468 Modified		Docket No. KUZ0035US.NP	Serial No. 10/594,887
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Fujinaga et al.	
U.S. Department of Commerce		Filing Date Not Assigned	Group Not Assigned

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

BA	Heppner et al., "Prevention of Scrapie Pathogenesis by Transgenic Expression of Anti-Prion Protein Antibodies", Science 2001 294:178-182
BB	White et al., "Monoclonal antibodies inhibit prion replication and delay the development of prion disease", Nature 2003 422:80-83
BC	Kurozumi et al., "BDNF Gene-Modified Mesenchymal Stem Cells Promote Functional Recovery and Reduce Infarct Size in the Rat Middle Cerebral Artery Occlusion Model", Molecular Therapy 2004 9(2):189-197
BD	Tsuda et al., "Efficient BMP2 Gene Transfer and Bone Formation of Mesenchymal Stem Cells by a Fiber-Mutant Adenoviral Vector", Molecular Therapy 2003 7(3):354-365
BE	Kobune et al., "Telomerized human multipotent mesenchymal cells can differentiate into hematopoietic and cobblestone area-supporting cells", Experimental Hematology 2003 31:715-722
BF	Xi et al., "Amphotericin B treatment dissociates <i>in vivo</i> replication of the scrapie agent from PrP accumulation", Nature 1992 356:598-601
BG	Caughey et al., "Potent Inhibition of Scrapie-Associated PrP Accumulation by Congo Red", J. Neurochem. 1992 59:768-771
BH	Tagliavini et al., "Effectiveness of Anthracycline Against Experimental Prion Disease in Syrian Hamsters", Science 1997 276:1119-1122
BI	Doh-Ura et al., "Lysosomotropic Agents and Cysteine Protease Inhibitors Inhibit Scrapie-Associated Prion Protein Accumulation", J. Virology 2000 74(10):4894-4897

EXAMINER	DATE CONSIDERED
----------	-----------------




Form PTO-1449 Modified		Docket No. KUZ0035US.NP	Serial No. 10/594,887
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Fujinaga et al.	
U.S. Department of Commerce		Filing Date Not Assigned	Group Not Assigned

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

BJ	Korth et al., "Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease", Proc. Natl. Acad. Sci. USA 2001 98(17):9836-9841
BK	Caughey et al., "Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines", Proc. Natl. Acad. Sci. USA 1998 95:12117-12122
BL	Kaneko et al., "Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation", Proc. Natl. Acad. Sci. USA 1997 94:10069-10074
BM	Solforosi et al., "Cross-Linking Cellular Prion Protein Triggers Neuronal Apoptosis in Vivo", Science 2004 303:1514-1516
BN	Enari et al., "Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody", Proc. Natl. Acad. Sci. USA 2001 98(16):9295-9299
BO	Peretz et al., "Antibodies inhibit prion propagation and clear cell cultures of prion infectivity", Nature 2001 412:739-743
BP	Gilch et al., "Polyclonal Anti-PrP Auto-antibodies Induced with Dimeric PrP Interfere Efficiently with PrP <sup>Sc</sup> Propagation in Prion-infected Cells", J. Biol. Chem. 2003 278(20):18524-18531
BQ	Büeler et al., "Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein", Nature 1992 356:577-582
BR	Yoshida et al., "Generation of Fiber-Mutant Recombinant Adenoviruses for Gene Therapy of Malignant Glioma", Human Gene Therapy 1998 9:2503-2515

EXAMINER	DATE CONSIDERED
----------	-----------------



Form PTO-1449 Modified		Docket No. KUZ0035US.NP	Serial No. 10/594,887
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Fujinaga et al.	
U.S. Department of Commerce		Filing Date Not Assigned	Group Not Assigned

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

BS	Kim et al., "Antigenic characterization of an abnormal isoform of prion protein using a new diverse panel of monoclonal antibodies", <i>Virology</i> 2004 320:40-51
BT	Yokoyama et al., <i>In Vivo Conversion of Cellular Prion Protein to Pathogenic Isoforms, as Monitored by Conformation-specific Antibodies</i> ", <i>J. Biol. Chem.</i> 2001 276(14):11265-11271
BU	Race et al., "Characterization of Scrapie Infection in Mouse Neuroblastoma Cells", <i>J. gen. Virol.</i> 1987 68:1391-1399
BV	Nakamura et al., "Effective Gene Transfer to Human Melanomas via Integrin-Targeted Adenoviral Vectors", <i>Human Gene Therapy</i> 2002 13:613-626
BW	Shibagaki et al., "Functional analysis of CD82 in the early phase of T cell activation:roles in cell adhesion and signal transduction", <i>Eur. J. Immunol.</i> 1998 28:1125-1133
BX	Shibagaki et al., "Overexpression of CD82 on human T cells enhances LFA-1/ICAM-1-mediated cell-cell adhesion:functional association between CD82 and LFA-1 in T cell activation", <i>Eur. J. Immunol.</i> 1999 29:4081-4091
BY	Linsley et al., "Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation", <i>J. Exp. Med.</i> 1991 173:721-730

EXAMINER	DATE CONSIDERED
----------	-----------------